Pui–Kei Wu

1.1k total citations
28 papers, 909 citations indexed

About

Pui–Kei Wu is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Pui–Kei Wu has authored 28 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Cell Biology. Recurrent topics in Pui–Kei Wu's work include Melanoma and MAPK Pathways (10 papers), Heat shock proteins research (5 papers) and Ginseng Biological Effects and Applications (4 papers). Pui–Kei Wu is often cited by papers focused on Melanoma and MAPK Pathways (10 papers), Heat shock proteins research (5 papers) and Ginseng Biological Effects and Applications (4 papers). Pui–Kei Wu collaborates with scholars based in United States, Hong Kong and China. Pui–Kei Wu's co-authors include Jong‐In Park, Seung‐Keun Hong, Andrew Becker, Dmytro Starenki, Zhi‐Hong Jiang, Ricky Ngok‐Shun Wong, P. Y. Leung, H.W. Yeung, N. K. Mak and L. Liu and has published in prestigious journals such as Molecular and Cellular Biology, Oncogene and Food Chemistry.

In The Last Decade

Pui–Kei Wu

27 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pui–Kei Wu United States 17 672 142 137 111 92 28 909
Joon‐Seok Choi South Korea 20 569 0.8× 182 1.3× 114 0.8× 75 0.7× 65 0.7× 50 990
Alok Ranjan United States 18 610 0.9× 242 1.7× 221 1.6× 114 1.0× 61 0.7× 38 1.1k
Tae Woo Kim South Korea 16 477 0.7× 107 0.8× 159 1.2× 179 1.6× 102 1.1× 34 820
Ji Wook Moon South Korea 18 637 0.9× 194 1.4× 160 1.2× 100 0.9× 47 0.5× 35 985
Biaoyan Du China 17 506 0.8× 118 0.8× 138 1.0× 121 1.1× 36 0.4× 34 793
A‐Mei Huang Taiwan 23 735 1.1× 232 1.6× 194 1.4× 56 0.5× 80 0.9× 51 1.2k
Chunfang Liu China 16 549 0.8× 141 1.0× 73 0.5× 71 0.6× 49 0.5× 36 827
Fangtian Fan China 18 414 0.6× 142 1.0× 192 1.4× 63 0.6× 46 0.5× 44 760

Countries citing papers authored by Pui–Kei Wu

Since Specialization
Citations

This map shows the geographic impact of Pui–Kei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pui–Kei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pui–Kei Wu more than expected).

Fields of papers citing papers by Pui–Kei Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pui–Kei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pui–Kei Wu. The network helps show where Pui–Kei Wu may publish in the future.

Co-authorship network of co-authors of Pui–Kei Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Pui–Kei Wu. A scholar is included among the top collaborators of Pui–Kei Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pui–Kei Wu. Pui–Kei Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Becker, Andrew, Pui–Kei Wu, Wenjing Chen, et al.. (2024). ERK1/2 interaction with DHPS regulates eIF5A deoxyhypusination independently of ERK kinase activity. Cell Reports. 43(10). 114831–114831. 1 indexed citations
2.
Leung, P. Y., et al.. (2024). Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. World Journal of Gastroenterology. 30(7). 714–727. 2 indexed citations
3.
Chen, Wenjing, Sophie Dream, P. Y. Leung, et al.. (2024). Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer. npj Precision Oncology. 8(1). 39–39. 4 indexed citations
4.
Wu, Pui–Kei, Seung‐Keun Hong, & Jong‐In Park. (2021). Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells. Cancer Letters. 502. 25–33. 16 indexed citations
5.
Wu, Pui–Kei, Seung‐Keun Hong, Wenjing Chen, et al.. (2020). Mortalin (HSPA9) facilitates BRAF -mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability. Science Signaling. 13(622). 28 indexed citations
6.
Wu, Pui–Kei, Dmytro Starenki, Kiyoko Oshima, et al.. (2020). Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene. 39(21). 4257–4270. 29 indexed citations
7.
Wu, Pui–Kei, Andrew Becker, & Jong‐In Park. (2020). Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway. International Journal of Molecular Sciences. 21(15). 5436–5436. 68 indexed citations
8.
Hong, Seung‐Keun, Pui–Kei Wu, & Jong‐In Park. (2017). A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. Cellular Signalling. 42. 11–20. 24 indexed citations
9.
Wu, Pui–Kei, Seung‐Keun Hong, & Jong‐In Park. (2017). Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells. Molecular and Cellular Biology. 37(18). 22 indexed citations
10.
Starenki, Dmytro, et al.. (2016). Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biology & Therapy. 18(2). 106–114. 21 indexed citations
11.
Wu, Pui–Kei & Jong‐In Park. (2015). MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Seminars in Oncology. 42(6). 849–862. 101 indexed citations
12.
Hong, Seung‐Keun, et al.. (2015). ERK1/2 can feedback-regulate cellular MEK1/2 levels. Cellular Signalling. 27(10). 1939–1948. 22 indexed citations
13.
Kim, Jin Hwan, Seung‐Keun Hong, Pui–Kei Wu, et al.. (2014). Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels. Experimental Cell Research. 327(2). 340–352. 96 indexed citations
14.
Wu, Pui–Kei, Seung‐Keun Hong, Sudhakar Veeranki, et al.. (2013). A Mortalin/HSPA9-Mediated Switch in Tumor-Suppressive Signaling of Raf/MEK/Extracellular Signal-Regulated Kinase. Molecular and Cellular Biology. 33(20). 4051–4067. 63 indexed citations
15.
Wu, Pui–Kei, William Tai, Roy C.Y. Choi, et al.. (2011). Chemical and DNA authentication of taste variants of Gynostemma pentaphyllum herbal tea. Food Chemistry. 128(1). 70–80. 28 indexed citations
16.
Wu, Pui–Kei, et al.. (2009). Primary Osteogenic Sarcoma with Pulmonary Metastasis: Clinical Results and Prognostic Factors in 91 Patients. Japanese Journal of Clinical Oncology. 39(8). 514–522. 97 indexed citations
17.
Wu, Pui–Kei, et al.. (2009). Oleanolic acid isolated from Oldenlandia diffusa exhibits a unique growth inhibitory effect against ras-transformed fibroblasts. Life Sciences. 85(3-4). 113–121. 35 indexed citations
18.
Wu, Pui–Kei, Kar Wah Leung, Nai Ki Mak, et al.. (2006). Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma. The International Journal of Biochemistry & Cell Biology. 38(8). 1393–1401. 11 indexed citations
19.
Yue, Patrick Ying‐Kit, Daisy Y.L. Wong, Pui–Kei Wu, et al.. (2006). The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochemical Pharmacology. 72(4). 437–445. 180 indexed citations
20.
Lau, George, et al.. (1999). CASE REPORT: Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer. Journal of Gastroenterology and Hepatology. 14(3). 262–268. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joon‐Seok Choi Breakdown of academic impact, for papers by Alok Ranjan Breakdown of academic impact, for papers by Tae Woo Kim Breakdown of academic impact, for papers by Ji Wook Moon Breakdown of academic impact, for papers by Biaoyan Du Breakdown of academic impact, for papers by A‐Mei Huang Breakdown of academic impact, for papers by Chunfang Liu Breakdown of academic impact, for papers by Fangtian Fan
Rankless by CCL
2026